Thursday, August 18, 2022 7:23:26 PM
I don’t think many appreciate exactly what the situation is. Suppose a climate scientist came up with a computer model that correctly produced results for the climate over the last five centuries, but atmospheric carbon dioxide was not a factor.
How much traction, publicity, or attention would he get. None. It completely goes against the consensus of scientists. The consensus controls the publications, research funds, and majority of news releases.
Now consider Alzheimer’s. The original research producing the ‘smoking gun’ for the cause of Alzheimer’s was published in 2006. It was only shown to be fraudulent this summer. What has happened over the last sixteen years? Students just beginning college in that year were were taught the ‘certainty’ of amyloid plaque causation of Alzheimer’s - and nothing else. Every student following them have been taught same thing. Many of those first students now have had their doctorates for over five years. Some may have their own labs, been published, and perhaps are recognized as an expert in the field of Alzheimer’s research. One of the co-authors of that original paper is now at the NIH, handing out grants for Alzheimer’s research. Guess what theory those who get the grants research.
Sixteen years is a long time to have been invested in a theory, and I don’t mean money. Careers, reputations, success, dreams of awards and prizes (Nobel, perhaps?) are all on the line. Imagine waking up one day hearing that the last sixteen years of your life have been a waste. That also goes for investors who have sunk millions of dollars into that theory.
I’m not surprised at all that Anavex is still under the radar. Too many people have too much to lose if Anavex is right. Don’t let any doubt creep in. Amyloid plaque causes Alzheimer’s. They must keep believing it, and the press must keep reporting it. They can’t afford to be wrong.
How much traction, publicity, or attention would he get. None. It completely goes against the consensus of scientists. The consensus controls the publications, research funds, and majority of news releases.
Now consider Alzheimer’s. The original research producing the ‘smoking gun’ for the cause of Alzheimer’s was published in 2006. It was only shown to be fraudulent this summer. What has happened over the last sixteen years? Students just beginning college in that year were were taught the ‘certainty’ of amyloid plaque causation of Alzheimer’s - and nothing else. Every student following them have been taught same thing. Many of those first students now have had their doctorates for over five years. Some may have their own labs, been published, and perhaps are recognized as an expert in the field of Alzheimer’s research. One of the co-authors of that original paper is now at the NIH, handing out grants for Alzheimer’s research. Guess what theory those who get the grants research.
Sixteen years is a long time to have been invested in a theory, and I don’t mean money. Careers, reputations, success, dreams of awards and prizes (Nobel, perhaps?) are all on the line. Imagine waking up one day hearing that the last sixteen years of your life have been a waste. That also goes for investors who have sunk millions of dollars into that theory.
I’m not surprised at all that Anavex is still under the radar. Too many people have too much to lose if Anavex is right. Don’t let any doubt creep in. Amyloid plaque causes Alzheimer’s. They must keep believing it, and the press must keep reporting it. They can’t afford to be wrong.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
